Impact of preoperative chemoradiation with higher dose intensity modulated radiotherapy on pathological complete response for locally advanced rectal cancer: a systematic review

References

• Yang Y, Liu Q, Jia B, et al. Preoperative volumetric modulated arc therapy with simultaneous integrated boost for locally advanced distal rectal cancer. Technol Cancer Res Treat. 2019;1(18):1533033818824367.
   Google Scholar
• Sauer R, Becker H, Hohenberger W, et al. German rectal cancer study group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740.
   PubMed Web of Science ®Google Scholar
• Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32(15):1554–1562.
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–844.
   PubMed Web of Science ®Google Scholar
• Beets GL, Maas M, Nelemans PJ, et al. Evaluation of response after chemoradiation for rectal cancer as a predictive factor for the benefit of adjuvant chemotherapy: a pooled analysis of 2,724 individual patients. J clin oncol. 2011;29(4):361.
   Web of Science ®Google Scholar
• Appelt AL, Vogelius IR, Ploen J, et al. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys. 2014;90(1):110–118.
   PubMed Web of Science ®Google Scholar
• Glynne -Jones R, Wyrwicz L, Tiret E, et al. ESMO clinical practice guidelines. Ann Oncol. 2017;28(suppl 4):iv22–iv 40 .
   PubMedGoogle Scholar
• Van der Valk MJM, DE H, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–2545.
   PubMed Web of Science ®Google Scholar
• Alongi F, Fersino S, Mazzola R, et al. Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. Clin Transl Oncol. 2017;19(2):189–196.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Kennedy CE, Fonner VA, Armstrong KA, et al. The evidence project risk of bias tool: assessing study rigor for both randomized and non-randomized intervention studies. Syst Rev. Systematic Reviews. 2019;8(1):3.
   PubMedGoogle Scholar
• Engels B, Tournel K, Everaert H, et al. Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):142–148.
   PubMed Web of Science ®Google Scholar
• Bipat S, Glas AS, Slors FJM, et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging - A meta-analysis. Radiology. 2004;232(3):773–783.
   PubMed Web of Science ®Google Scholar
• Ortega CD, Perez RO. Role of magnetic resonance imaging in organ-preserving strategies for the management of patients with rectal cancer. Insights Imaging. 2019;10(1):59.
   PubMed Web of Science ®Google Scholar
• Liang TY, Anil G, Ang BWL, et al. Imaging paradigms in assessment of rectal carcinoma: loco-regional and distant staging. Cancer Imaging. 2012;12(1):290–303.
   PubMed Web of Science ®Google Scholar
• Burton S, Brown G, Daniels I, et al. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65(2):445–451.
   PubMed Web of Science ®Google Scholar
• Furey E, Jhaveri KS. Magnetic resonance imaging in rectal cancer. Magn Reson Imaging Clin N Am. 2014;22(2):165–90, v–vi.
   Web of Science ®Google Scholar
• Costa-Silva L, Brown G. Magnetic resonance imaging of rectal cancer. Magn Reson Imaging Clin N Am. 2013;21(2):385–408.
   PubMed Web of Science ®Google Scholar
• Barbaro B, Fiorucci C, Tebala C, et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology. 2009;250(3):730–739.
   PubMed Web of Science ®Google Scholar
• Beets-Tan RGH, Beets GL, Vliegen RFA, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet. 2001;357(9255):497–504.
   PubMed Web of Science ®Google Scholar
• Messina C, Bignone R, Bruno A, et al. Diffusion-weighted imaging in oncology: an update. Cancers (Basel). 2020;12(6):1–28.
   Web of Science ®Google Scholar
• Thomeer MG, Vandecaveye V, Braun L, et al. Evaluation of T2-W MR imaging and diffusion-weighted imaging for the early post-treatment local response assessment of patients treated conservatively for cervical cancer: a multicentre study. Eur Radiol. 2019;29(1):309–318.
   PubMed Web of Science ®Google Scholar
• Foti PV, Privitera G, Piana S, et al. Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapy-NC-ND license. Eur J Radiol Open. 2016;3:145–152.
   PubMed Web of Science ®Google Scholar
• Lambregts DMJ, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol. 2011;18(8):2224–2231.
   PubMed Web of Science ®Google Scholar
• Schurink NW, Lambregts DMJ, Beets-Tan RGH, et al. Diffusion-weighted imaging in rectal cancer: current applications and future perspectives. Br J Radiol. 2019;92(1096):20180655.
   PubMed Web of Science ®Google Scholar
• Rymer B, Curtis NJ, Siddiqui MRS, et al. FDG PET/CT can assess the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy: evidence from meta-analysis and systematic review. Clin Nucl Med. 2016;41(5):371–375.
   PubMed Web of Science ®Google Scholar
• Memon S, Lynch AC, Akhurst T, et al. Systematic Review of FDG-PET Prediction of Complete Pathological Response and Survival in Rectal Cancer. Ann Surg Oncol. 2014;21(11):3598–3607.
   PubMed Web of Science ®Google Scholar
• Janssen MHM, Öllers MC, Riedl RG, et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using 18F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys. 2010;77(2):392–399.
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Herrmann K, Gertlerr R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis. 2009;24(2):191–200.
   PubMed Web of Science ®Google Scholar
• Maffione AM, Marzola MC, Capirci C, et al. Value of 18 F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. Am J Roentgenol. 2015;204(6):1261–1268.
   PubMed Web of Science ®Google Scholar
• Zhang C, Tong J, Sun X, et al. 18 F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. Int J Cancer. 2012;131(11):2604–2611.
   PubMed Web of Science ®Google Scholar
• Janssen MHM, Öllers MC, van Stiphout RGPM, et al. PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiat Oncol Biol Phys. 2012;82(2):871–876.
   PubMed Web of Science ®Google Scholar
• Pyo DH, Choi JY, Lee WY, et al. A nomogram for predicting pathological complete response to neoadjuvant chemoradiotherapy using semiquantitative parameters derived from sequential PET/CT in locally advanced rectal cancer. Front Oncol. 2021;11. doi: 10.3389/fonc.2021.742728.
   PubMed Web of Science ®Google Scholar
• Alongi P, Laudicella R, Desideri I, et al. Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. Crit Rev Oncol Hematol. 2019;140:74–79.
   PubMed Web of Science ®Google Scholar
• Fiorentino A, Laudicella R, Ciurlia E, et al. AIRO Giovani - Italian association of radiation oncology-young members and AIMN -Italian association of nuclear medicine-young members working group. Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Crit Rev Oncol Hematol. 2019;139:117–124.
   PubMed Web of Science ®Google Scholar
• Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008;72(1):99–107.
   PubMed Web of Science ®Google Scholar
• Ortholan C, Romestaing P, Chapet O, et al. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial. Int J Radiat Oncol Biol Phys. 2012;83(2):e165–71.
   PubMed Web of Science ®Google Scholar
• Valentini V, Van Stiphout RGPM, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of european randomized clinical trials. J Clin Oncol. 2011;29(23):3163–3172.
   PubMed Web of Science ®Google Scholar
• Appelt AL, Pløen J, Vogelius IR, et al. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80.
   PubMed Web of Science ®Google Scholar
• Freedman GM, Meropol NJ, Sigurdson ER, et al. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007;67(5):1389–1393.
   PubMed Web of Science ®Google Scholar
• Picardi V, Macchia G, Guido A, et al. Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study. Clin Colorectal Cancer. 2017;16(1):16–22.
   PubMed Web of Science ®Google Scholar
• Ballonoff A, Kavanagh B, McCarter M, et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008;31(3):264–270.
   PubMed Web of Science ®Google Scholar
• But-Hadzic J, Anderluh F, Brecelj E, et al. Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost: a phase 2 trial. Int J Radiat Oncol Biol Phys. 2016;96(5):1003–1010.
   PubMed Web of Science ®Google Scholar
• Li JL, Ji JF, Cai Y, et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial. Radiother Oncol. 2012;102(1):4–9.
   PubMed Web of Science ®Google Scholar
• Zhu J, Liu F, Gu W, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol. 2014;9(70). doi:10.1186/1748-717X-9-70
   Google Scholar
• Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262.
   PubMedGoogle Scholar
• Guerrero Urbano MT, Henrys AJ, Adams EJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006;65(3):907–916.
   PubMed Web of Science ®Google Scholar
• Arbea L, Ramos LI, Martinez-Monge R, et al. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5(1):1–19.
   PubMedGoogle Scholar
• Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Bio Phys L. 2005;63(2):354–361.
   PubMedGoogle Scholar
• Caravatta L, Padula GD, Picardi V, et al. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study. Acta Oncol. 2011;50(8):1151–1157.
   PubMed Web of Science ®Google Scholar
• Samuelian JM, Callister MD, Ashman JB, et al. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):1981–1987.
   PubMed Web of Science ®Google Scholar
• Mok H, Crane CH, Palmer MB, et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol. 2011;6(1):1–9.
   PubMedGoogle Scholar
• Cusumano D, Boldrini L, Yadav P, et al. External validation of early regression index (ERITCP) as predictor of pathologic complete response in rectal cancer using magnetic resonance-guided radiation therapy. Int J Radiat Oncol Biol Phys. 2020;108(5):1347–1356.
   PubMed Web of Science ®Google Scholar
• Boldrini L, Cusumano D, Chiloiro G, et al. Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. Radiol Med. 2019;124(2):145–153.
   PubMed Web of Science ®Google Scholar
• Abdalmassih M, Sivananathan G, Railman Z, et al. Prognostic markers of recurrence and survival in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. Colorectal Cancer. 2018; 7(1):CRC02.
   Web of Science ®Google Scholar
• Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012;19(9):2822–2832.
   PubMed Web of Science ®Google Scholar
• de Campos-Lobato LF, Stocchi L, da Luz MA, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. Annals of Surgical Oncology. 2011;18(6):1590–1598.
   PubMed Web of Science ®Google Scholar
• On J, Shim J, Mackay C, et al. Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival. Colorectal Disease. 2021;23(6):1326–1333.
   PubMed Web of Science ®Google Scholar
• Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Rad Onc Biol Phys. 2005;62(3):752–760.
   PubMed Web of Science ®Google Scholar
• Belluco C, De Paoli A, Canzonieri V, et al. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol. 2011;18(13):3686–3693.
   PubMed Web of Science ®Google Scholar
• JY Li, Huang X, Gao P, et al. Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data. BMC Cancer. 2021;21(1):1–11.
   PubMed Web of Science ®Google Scholar
• Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47(11):1798–1807.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol. 2017;8(1):39–48.
   PubMed Web of Science ®Google Scholar
• Kasi A, Abbasi S, Handa S, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Network Open. 2020;3(12(12):e2030097.
   Web of Science ®Google Scholar
• Delli Pizzi A, Chiarelli AM, Chiacchiaretta P, et al. MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer. Sci Rep. 2021;11(1):1–11.
   PubMedGoogle Scholar